Humana Inc. (NYSE:HUM) Shares Acquired by Solel Partners LP

Solel Partners LP boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 48.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 199,800 shares of the insurance provider’s stock after buying an additional 65,000 shares during the quarter. Humana comprises 12.2% of Solel Partners LP’s portfolio, making the stock its biggest holding. Solel Partners LP owned 0.17% of Humana worth $74,655,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Pzena Investment Management LLC lifted its stake in shares of Humana by 538.7% in the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after buying an additional 1,955,375 shares during the last quarter. Davis Selected Advisers boosted its holdings in Humana by 16.1% during the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after acquiring an additional 321,233 shares during the period. Marshall Wace LLP increased its stake in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares during the period. Sanders Capital LLC bought a new position in shares of Humana in the fourth quarter worth about $489,300,000. Finally, Ontario Teachers Pension Plan Board lifted its position in shares of Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after purchasing an additional 1,050,459 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

NYSE:HUM opened at $312.74 on Tuesday. The stock has a market capitalization of $37.69 billion, a P/E ratio of 19.47, a price-to-earnings-growth ratio of 2.56 and a beta of 0.50. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The firm has a 50 day moving average of $356.28 and a 200-day moving average of $345.36. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.94 EPS. As a group, sell-side analysts anticipate that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.13%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio is presently 22.04%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price target on shares of Humana in a report on Friday. TD Cowen raised their price target on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. JPMorgan Chase & Co. boosted their price objective on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Deutsche Bank Aktiengesellschaft lifted their target price on Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research report on Friday, August 2nd. Finally, Truist Financial upped their price target on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a report on Monday, July 15th. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.